

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kilgannon et al.

Serial No. 10/025,524

Filed: December 18, 2001

Title: ICAM-4 Materials and Methods

Group Art Unit: 1645

Examiner: Patricia Duffy

I hereby certify that this paper is being deposited with the United States Postal Service on December 2, 2004 in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, utilizing the "Express Mail Post Office to Addressee" service of the United States Postal Service under Mailing Label No. EV323774642US.

Richard Zimmermann

AMENDMENT AND RESPONSE UNDER 37 C.F.R. §1.111

**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

Dear Sir:

INTRODUCTORY REMARKS

This paper is filed in response to a Final Office Action (hereinafter "the Action") from the U.S. Patent and Trademark Office, mailed June 2, 2004. In the Action, the Examiner maintained the rejection of claim 27 under 35 U.S.C. § 112, first paragraph, for assertedly lacking written description and under 35 U.S.C. § 103 (a) as assertedly unpatentable in light of Oka *et al.*, (Neuroscience 35:93-103, 1990) (hereinafter "Oka"), in view of Yoshihara *et al.*, (Neuron, 12:541-44, 1994) (hereinafter "Yoshihara") and further in view of Goding *et al.*, (Monoclonal Antibodies, 1983 Academic Press Inc.) (hereinafter "Goding"). In view of the following amendments and remarks, reconsideration is respectfully requested.

Remarks begin on page 2 of this paper.

A Notice of Appeal and check in pursuant to 37 CFR 1.17 (b) accompanies this paper. -